Voiding Efficiency, a Predictor of Clean Intermittent Catheterization (CIC)

Completed

Conditions studied: Urinary Bladder, Overactive

In brief

This study is a retrospective chart review of patients treated with onabotulinumtoxinA (BOTOX®) for idiopathic overactive bladder (OAB) and will determine voiding efficiency (VE) cutoff ratios that predict post-procedure urinary retention requiring catheterization.

Key facts

Study ID

NCT03043287

Run by

Allergan

People needed

420

Starts

2017-05-12

Expected to finish

2019-09-30

Last updated by the study team

2020-02-05

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Patient with documented idiopathic OAB diagnosis
• Patient was treated with 100-200U of BOTOX® for OAB
• Urodynamics assessment within prior to first BOTOX® injection.

You may not qualify if…

• Patient had received botulinum toxin formulations other than BOTOX® in the bladder
• Patient had symptoms of OAB associated with a neurological condition (eg, spinal cord injury, multiple sclerosis, cerebrovascular accident, Alzheimer's disease, Parkinson's disease, etc).

Where it is running

• Regional Urology — Shreveport, Louisiana, United States
• Chesapeake Urology Associates, LLC — Baltimore, Maryland, United States
• Virginia Urology — Richmond, Virginia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.